← All trials
NCT05583838
Phase 4Interventional
Studies of FDA-approved drugs to delineate additional information including the drug's risks, benefits, and optimal use.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Oct 31, 2022
- Primary completion
- Jun 30, 2024
- Completion date
- Dec 31, 2024
- First posted
- Oct 18, 2022
- Last posted
- Oct 18, 2022
- Enrollment
- 175
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- China Academy of Chinese Medical SciencesLead sponsor
- Chinese Academy of Medical SciencesOverall official - principal investigator
- Xinjiang Medical UniversityCollaborator
- Henan Medical UniversityCollaborator
- China Academy of Chinese Medical SciencesReponsible party - principal investigator
- North China University of Science and Technology Affiliated HospitalCollaborator
- Xinjiang Medical UniversityCollaborator
- Guangzhou Medical UniversityCollaborator
- Shanxi Medical UniversityCollaborator
- Shaanxi Provincial People's HospitalCollaborator
- Sunshine Lake Pharma Co., Ltd.Collaborator
- Inner Mongolia Medical UniversityCollaborator
- Dalian Medical UniversityCollaborator
- Harbin Medical UniversityCollaborator
- Kunming Medical UniversityCollaborator
- Jiao Tong UniversityCollaborator
- Xijing HospitalCollaborator
- Kashgar 1st People's HospitalCollaborator
- Chinese Academy of Medical SciencesOfficial
- Yuyao People's Hospital of Zhejiang ProvinceCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.